Malignant Melanoma Linked to Parkinson's Disease

2005 ◽  
Vol 36 (11) ◽  
pp. 37
Author(s):  
TIMOTHY F. KIRN
2012 ◽  
Vol 131 (8) ◽  
pp. 1904-1911 ◽  
Author(s):  
Kathrine Rugbjerg ◽  
Søren Friis ◽  
Christina Funch Lassen ◽  
Beate Ritz ◽  
Jørgen H. Olsen

2016 ◽  
Vol 48 ◽  
pp. 222.e1-222.e7 ◽  
Author(s):  
S.J. Lubbe ◽  
V. Escott-Price ◽  
A. Brice ◽  
T. Gasser ◽  
A.M. Pittman ◽  
...  

Ophthalmology ◽  
1982 ◽  
Vol 89 (12) ◽  
pp. 1464-1466 ◽  
Author(s):  
Gerard H. Van Rens ◽  
Paul T.V.M. Jong ◽  
Emiel E.J.L.R. Demols ◽  
Marthe F. Brihaye-Van Geertruyden

2000 ◽  
Vol 34 (3) ◽  
pp. 382-385 ◽  
Author(s):  
Jolene F Siple ◽  
Diana C Schneider ◽  
Wendy A Wanlass ◽  
Burton K Rosenblatt

OBJECTIVE: To evaluate the use of levodopa therapy in patients with Parkinson's disease and malignant melanoma. DATA SOURCES: A MEDLINE search (January 1966–September 1999) of English-language articles was conducted. Key search terms included levodopa, melanoma, and Parkinson's disease; 34 case reports were identified. DATA SYNTHESIS: Carbidopa/levodopa continues to be a mainstay in the treatment of Parkinson's disease. Since the late 1970s, a warning has appeared in the prescribing literature for levodopa regarding the risk of activating malignant melanoma. An evaluation was conducted of the case reports in which a causal relationship between levodopa and melanoma was suggested. CONCLUSIONS: There is an unlikely association between levodopa and induction or exacerbation of malignant melanoma.


2015 ◽  
Vol 87 (3) ◽  
pp. 302-310 ◽  
Author(s):  
Uwe Walter ◽  
Elise Heilmann ◽  
Johannes Voss ◽  
Katrin Riedel ◽  
Andrey Zhivov ◽  
...  

2003 ◽  
Vol 9 (6) ◽  
pp. 321-327 ◽  
Author(s):  
Katherine H Fiala ◽  
Jacqueline Whetteckey ◽  
Bala V Manyam

Sign in / Sign up

Export Citation Format

Share Document